

Cary L. Queen et al.
Serial No.: 08/484,537
Page 2

PATENT

collecting said humanized immunoglobulin produced by the host cell.

--107. A method according to claim 106 wherein the antigen is the human CD33 antigen.

--108. A method for producing a humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains,

the method comprising substituting one or more amino acids from the donor immunoglobulin heavy chain framework outside the Kabat and Chothia CDRs for the corresponding amino acids in the acceptor immunoglobulin heavy chain framework, wherein said donor amino acid:

(I) is adjacent to a CDR in the donor immunoglobulin sequence, or

(II) is capable of interacting with amino acids in the CDRs, or

(III) is typical at its position for human immunoglobulin sequences, and the substituted amino acid in the acceptor is rare at its position for human immunoglobulin sequences;

wherein the humanized immunoglobulin specifically binds to an antigen with an affinity constant of a least $10^7 M^{-1}$.

--109. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an affinity constant stronger than $10^7 M^{-1}$, wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside the Kabat and Chothia CDRs that replace the corresponding amino acids in the acceptor